You are here

milademetan

Rain Oncology is latest troubled biotech to receive acquisition offer from Concentra

Fierce Biotech

Mon, 10/16/23 - 11:37 pm

Concerta Biosciences

Rain Oncology to cut 65% of staff after milademetan Phase 3 trial failure

Medical Marketing and Media

Wed, 05/31/23 - 11:00 am

clinical trials

Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3

Tip Ranks

Wed, 05/24/23 - 10:14 am

clinical trials